Cargando…

Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study

BACKGROUND: The effects of sorafenib in the treatment of advanced renal cell carcinoma (RCC) have been confirmed in an international collaborative phase III trial. This study aims to confirm similar efficacy and treatment-induced toxicities of sorafenib in the treatment of metastatic RCC in ethnic C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Hailiang, Dong, Baijun, Lu, Jiade J, Yao, Xudong, Zhang, Shilin, Dai, Bo, Shen, Yijun, Zhu, Yao, Ye, Dingwei, Huang, Yiran
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724546/ https://www.ncbi.nlm.nih.gov/pubmed/19622166 http://dx.doi.org/10.1186/1471-2407-9-249

Ejemplares similares

Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer
por: Wan, Fangning, et al.
Publicado: (2014)

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
por: Qin, Shukui, et al.
Publicado: (2015)

Upregulation of COL6A1 is predictive of poor prognosis in clear cell renal cell carcinoma patients
por: Wan, Fangning, et al.
Publicado: (2015)

Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status
por: Wu, Junlong, et al.
Publicado: (2017)

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
por: Cai, Wen, et al.
Publicado: (2017)

Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma
por: Fangning, Wan, et al.
Publicado: (2017)

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
por: Yang, Lin, et al.
Publicado: (2018)

B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma
por: Qin, Xiaojian, et al.
Publicado: (2013)

Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients
por: Wu, Junlong, et al.
Publicado: (2017)

AB032. Penile rehabilitation using Vacuum Erection Device for erectile dysfunction after radical prostatectomy
por: Ye, Dingwei, et al.
Publicado: (2015)

PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness
por: Chang, Kun, et al.
Publicado: (2017)

Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?
por: Zhang, Guiming, et al.
Publicado: (2014)

Serum Adiponectin Level May be an Independent Predictor of Clear Cell Renal Cell Carcinoma
por: Wang, Hongkai, et al.
Publicado: (2016)

Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
por: Gu, Weijie, et al.
Publicado: (2017)

The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma
por: Qin, Chao, et al.
Publicado: (2016)

Comprehensive Analysis of BAP1 Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms in Silico
por: Jin, Shengming, et al.
Publicado: (2018)

The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma
por: Xu, Fujiang, et al.
Publicado: (2017)

Retrograde radical cystectomy and consequent peritoneal cavity reconstruction benefits localized male bladder cancer: results from a cohort study
por: Qin, Xiaojian, et al.
Publicado: (2015)

Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study
por: Qin, Xiaojian, et al.
Publicado: (2015)

PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine/chemokine receptor interaction pathway
por: Wang, HongKai, et al.
Publicado: (2017)

Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma
por: Gu, Weijie, et al.
Publicado: (2015)

Author Correction: The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma
por: Xu, Fujiang, et al.
Publicado: (2018)

High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma
por: Cao, Dalong, et al.
Publicado: (2018)

Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients
por: Anwaier, Aihetaimujiang, et al.
Publicado: (2022)

Complicated variation of simple renal cyst usually means malignancy: results from a cohort study
por: Qin, XiaoJian, et al.
Publicado: (2014)

Basal cell carcinoma of the prostate: clinicopathologic analysis of three cases and a review of the literature
por: Chang, Kun, et al.
Publicado: (2013)

Identification and validation of an 18-gene signature highly-predictive of bladder cancer metastasis
por: Wang, Beihe, et al.
Publicado: (2018)

Expression of Dicer and Its Related MiRNAs in the Progression of Prostate Cancer
por: Bian, Xiaojie, et al.
Publicado: (2015)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Successful treatment with sorafenib for sunitinib‐refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib
por: Morinaga, Ryota, et al.
Publicado: (2018)

ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A
por: Wang, Yuchen, et al.
Publicado: (2021)

Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib
por: Lu, Xiaolin, et al.
Publicado: (2016)

Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib
por: Li, Zhi Yong, et al.
Publicado: (2016)

Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer
por: Abudurexiti, MierXiati, et al.
Publicado: (2019)

Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study
por: Kim, Sung Han, et al.
Publicado: (2015)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study
por: Wei, Di, et al.
Publicado: (2019)

Adverse Effect of Lymph Node Dissection in Metastatic Renal Cell Cancer Patients Treated with Cytoreductive Nephrectomy: A Contemporary Analysis of Survival
por: Cao, Dalong, et al.
Publicado: (2019)

Extramammary Paget’s diseases in men from the Shanghai area: its association with PSA level increase*
por: SHI, GUOHAI, et al.
Publicado: (2010)

The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China
por: Zheng, Yu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6rkrqjsusnhojdh72ccadgbrmh